Dysplasia and colorectal cancer in inflammatory bowel disease: A result of inflammation or an intrinsic risk?

Acta Gastro-Enterologica Belgica

Volumn 71, Issue 4, 2008, Pages 367-372

  Breynaert, C ^a   Venneire, S ^a   Rutgeerts, P ^a   Van Assche, Gert ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2;

APOPTOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CELL DAMAGE; CHROMOSOME ABERRATION; COLON CARCINOGENESIS; COLORECTAL CANCER; CONGENITAL DISORDER OF GLYCOSYLATION; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; DNA DAMAGE; DYSPLASIA; ENTERITIS; ENZYME ACTIVITY; FAMILY HISTORY; GENOMIC INSTABILITY; HUMAN; ILEITIS; INFLAMMATION; INTESTINE CRYPT; MICROSATELLITE INSTABILITY; MOLECULAR DYNAMICS; ONSET AGE; OXIDATIVE STRESS; PATHOGENESIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; RISK FACTOR; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS;

COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS;

EID: 60849090469     PISSN: 00015644     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. WEITZ J., KOCH M., DEBUS J., HÖHLER T., GALLE P.R., BÜCHLER M.W. Colorectal cancer. Lancet, 2005, 365: 153-165.
2. JESS T., GAMBORG M., MATZEN P., MUNKHOLM P., SORENSEN T.I. Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol, 2005, 100: 2724-2729.
3. EADEN J.A., ABRAMS K.R., MAYBERRY J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 2001, 48: 526-535.
4. CANAVAN C., ABRAMS K.R., MAYBERRY J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol. Ther., 2006, 23: 1097-1104.
5. MUNKHOLM P. The incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol. Ther., 2003, 18 (suppl. 2): 1-5.
6. RUTTER M.D., SAUNDERS B.P., WILKINSON K.H. et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology, 2006, 130: 1030-1038.
7. FRIEDMAN S. Cancer in Crohn's Disease. Gastroenterol. Clin. North Am., 2006, 35: 621-639.
8. LOFTUS E.V. Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis. Gastroenterol Clin. North Am., 2006, 35: 517-531.
9. RHODES J.M., CAMPBELL B.J. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol. Med., 2002, 8: 10-16.
10. ITZKOWITZ S. Colon carcinogenesis in inflammatory bowel disease. Applying molecular genetics to clinical practice. J. Clin. Gastroenterol., 2003, 36 (Suppl. 1): S70-S74.
11. ITZKOWITZ S.H., YIO X. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am. J. Physiol. Gastrointest. Liver Physiol., 2004, 287: 7-17.
12. EKBOM A., HELMICK C., ZACK M., ADAMI H.O. Ulcerative colitis and colorectal cancer. A population-based study. N. Engl. J. Med., 1990, 323: 1228-1233.
13. LUTGENS M.W., VLEGGAAR F.P., SCHIPPER M.E. et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut, 2008, 57: 1246-125.
14. ITZKOWITZ S.H., PRESENT D.H. Consensus conference: colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm. Bowel Dis., 2005, 11: 314-321.
15. JESS T., LOFTUS E.V., VELAYOS F.S. et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology, 2006, 130: 1039-1313.
16. EADEN J.A., MAYBERRY J.F. Colorectal cancer complicating ulcerative colitis: a review. Am. J. Gastroenterol., 2000, 95: 2710-2719.
17. BRACKMANN S., ANDERSEN S.N., AAMODT G. et al. Two distinct groups of colorectal cancer in inflammatory bowel disease. Inflam. Bowel Dis., 2008, Jul 10 (Epub ahead of print).
18. EDWARDS F.C., TRUELOVE S.C. The course and prognosis of ulcerative colitis. Part IV: carcinoma of the colon. Gut, 1964, 5: 15-22.
19. PRIOR P., GYDE S.N., MACARTNEY J.C., THOMPSON H., WATERHOUSE J.A., ALLAN R.N. Cancer morbidity in ulcerative colitis. Gut, 1982, 23: 490-497.
20. EADEN J., ABRAMS K., EKBOM A., JACKSON E., MAYBERRY J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol. Ther., 2000, 14: 145-153.
21. PINCZOWSKI D., EKBOM A., BARON J., YUEN J., ADAMI H.O. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology, 1994, 107: 117-120.
22. RUTTER M., SAUNDERS B., WILKINSON K. et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology, 2004, 126: 451-459.
23. RUTTER M.D., SAUNDERS B.P., WILKINSON K.H. et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut, 2004, 53: 1813-1816.
24. JESS T., LOFTUS E.V., VELAYOS F.S. et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen County, Denmark and Olmsted County, Minnesota. Am. J. Gastroenterol., 2007, 102: 1-8.
25. BROOME U., LOFBERG R., VERESS B., ERIKSSON L.S. Primary sclerosing cholangitis and ulcerative colitis. Evidence for increased neoplastic potential. Hepatology, 1995, 22: 1404-1408.
26. D'HAENS G.R., LASHNER B.A., HANAUER S.B. Pericholangitis and sclerosing cholangitis are risk factors for dysplasia and cancer in ulcerative colitis. Am. J. Gastroenterol., 1993, 88: 1174-1178.
27. PINCOZOWSKI D., EKBOM A. Is there an increased risk of colorectal cancer among ulcerative colitis patients with primary sclerosing cholangitis? Gastroenterology, 1995, 108: A29.
28. LOFTUS E.V., SANDBORN W.J., TREMAINE W.J. et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis. Gastroenterology, 1996, 110: 432-440.
29. LOFTUS E.V., AGUILAR H.I., SANDBORN W.J. et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology, 1998, 27: 685-690.
30. HEUSCHEN U.A., HINZ U., ALLEMEYER E.H. et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology, 2001, 120: 841-847.
31. LOFTUS E.V., HAREWOOD G.C., LOFTUS C.G. et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut, 2005, 36: 321-327.
32. HASKELL H., ANDREWS C.W., REDDY S.I. et al. Pathologic features and clinical significance of "backwash" ileitis in ulcerative colitis. Am. J. Surg. Pathol., 2005, 29: 1472-1481.
33. FUCHS C.S., GIOVANNUCCI E.L., COLDITZ G.A., HUNTER D.J., SPEIZER F.E., WILLETT W.C. A prospective study of family history and the risk of colorectal cancer. N. Engl. J. Med., 1994, 331: 1669-1674.
34. EADEN J., ABRAMS K., EKBOM A., JACKSON E., MAYBERRY J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol. Ther., 2000, 14: 145-153.
35. ASKLING J., DICKMAN P.W., KARLEN P. et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology, 2001, 120: 1356-1362.
36. VELAYOS F.S., LOFTUS E.V., JESS T. et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology, 2006, 130: 1941-1949.
37. ITZKOWITZ S.H., HARPAZ N. Diagnosis and management of dysplasia in patients with inflammatory bowel diseases. Gastroenterology, 2004, 126: 1634-1648.
38. LOFBERG R., LINDQUIST K., VERESS B., TRIBUKAIT B. Highly malignant carcinoma in chronic ulcerative colitis without preceding dysplasia or DNA aneuploidy. Dis. Colon Rectum, 1992, 35: 82-86.
39. WILLENBUCHER R.F., AUST D.E., CHANG C.G. et al. Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am. J. Pathol., 1999, 154: 1825-1830.
40. ITZKOWITZ S.H. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol. Clin. North Am., 2006, 35: 553-571.
41. RABINOVITCH P.S., DZIADON S., BRENTNALL T.A. et al. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer res., 1999, 59: 5148-5153.
42. HUSSAIN S.P., AMSTAD P., RAJA K. et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory bowel disease. Cancer Res., 2000, 60: 3333-3337.
43. YASHIRO M., CARETHERS J.M., LAGHI L. et al. Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. Cancer Res., 2001, 61: 2676-2683.
44. HUSSAIN S.P., HOFSETH L.J., HARRIS C.C. Radical causes of cancer. Nature Rev. Cancer, 2003, 267: 267-285.
45. CHANG C.L., MARRA G., CHAUHAN D.P. et al. Oxidative stress inactivates the human DNA mismatch repair system. Am. J. Physiol. Cell. Physiol., 2002, 283: C148-154.
46. CHEN R., RABINOVITCH P.S., CRISPIN D.A., EDMOND M.J., BRONNER M.P., BRENTNALL T.A. The initiation of colon cancer in a chronic inflammatory setting. Carcinogenesis, 2005, 9: 1513-1519.
47. SHIH I.M., WANG T.L., TRAVERSO G. et al. Top-down morphogenesis of colorectal tumors. Proc. Natl. Acad. Sci. USA, 2001, 98: 2640-2645.
48. OSHIMA M., TAKETO M.M. COX selectivity and animal models for colon cancer. Curr. Pharm. Des., 2002, 8: 1021-1034.
49. ULLMAN T., CROOG V., HARPAZ N., ITZKOWITZ S., KORNBLUTH A. Preventing neoplastic progression in ulcerative colitis. Gastroenterology, 2003, 124 (suppl 1): A242.
50. VELAYOS F.S., TERDIMAN J.P., WALSH J.M. Effects of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am. J. Gastroenterol., 2005, 100: 1345-1353.
51. VAN STAA T.P., CARD T., LOGAN R.F., LEUFKENS H.G. 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut, 2005, 54: 1573-1578.
52. TERDIMAN J.P., STEINBUCH M., BLUMENTALS W.A., ULLMAN T.A., RUBIN D.T 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm. Bowel Dis., 2007, 13: 367-371.
53. MATULA S., CROOG V., ITZKOWITZ S. et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin. Gastroenterol. Hepatol., 2005, 3: 1015-1021.
54. RUTGEERTS P., VERMEIRE S., VAN ASSCHE G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut, 2007, 56: 453-455.
55. POPIVANOVA B.K., KITAMURA K., WU Y. et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J. Clin. Invest., 2008, 118: 560-570.
56. RHODES J.M. Unifying hypothesis for inflammatory bowel disease and related colon cancer: sticking the pieces together with sugar. Lancet, 1996, 347: 40-44.
57. CAMPBELL B.J., YU L., RHODES J.M. Altered glycosylation in inflammatory bowel disease: a possible role in cancer development. Glycoconj. J., 2001, 18: 851-858.
58. ASKLING J., DICKMAN P.W., KARLEN P. et al. Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet, 2001, 357: 262-266.